BACKGROUND
In 2013 our protocol of restricted use antibiotics (RUA) was updated & computerized. The following drugs were subject to their respective indications: Ertapenem: Community intra-abdominal infection with risk factors, moderate or severe diabetic foot infections and outpatient management. Linezolid: pneumonia, diabetic foot infections, osteomyelitis and prosthetic infections & serious bile duct infections. Daptomycin: endocarditis, diabetic foot infections, osteomyelitis and prosthetic infections and right-sided endocarditis. Tigecycline: complicated intra-abdominal infections or soft tissue infections, except diabetic foot infections, if there is not alternative.

PURPOSE
Evaluate RUA outcomes one year after implementation.

RESULTS
500 requests for RUA were conducted: 22% ertapenem, 37.2% linezolid, 35.2% daptomycin and 5.6% tigecycline. The antibiotics were used as is represented in figure 1:

The RUA spending in 2013 compared to the previous year decreased by € 31,843. Daptomycin increased slightly (€ 1,461) while consumption of tigecycline and ertapenem was reduced by € 14,254 and € 13,131 respectively. This is a 45.7% and 31.5% costs reduction over the previous year. Linezolid in spending was also reduced € 5,920€. Slightly 2% over the previous year

Conclusion
The update and computerization of RUA protocol has achieved a reduction in spending on these antibiotics and improves the adjust of the prescriptions to the current indications of these drugs.

Acknowledgements
Hospital Computing Service.